The heterozygous loss of retinoblastoma (RB) and other components of the RB pathway, including cyclin-dependent kinase (CDK) inhibitors p18 and p27, are involved in MTC tumorigenesis in murine models and in human tumor samples [49,50]. Here, RB1 is linked to neoplasm.